+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PDGFR Inhibitor Market by Indication (Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors), Drug Type (Monoclonal Antibody, Small Molecule Inhibitor), Delivery Route, End User, Sales Channel - Global Forecast 2025-2030- Product Image
PDGFR Inhibitor Market by Indication (Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors), Drug Type (Monoclonal Antibody, Small Molecule Inhibitor), Delivery Route, End User, Sales Channel - Global Forecast 2025-2030- Product Image
Sale

PDGFR Inhibitor Market by Indication (Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors), Drug Type (Monoclonal Antibody, Small Molecule Inhibitor), Delivery Route, End User, Sales Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016422
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives in the biopharmaceutical industry face a complex and evolving PDGFR Inhibitor Market marked by continuous scientific innovation, changing regulatory environments, and shifting competitive dynamics. This research report offers the clarity required to formulate resilient strategies in targeted oncology and precision medicine.

Market Snapshot: PDGFR Inhibitor Market Size and Trajectory

The PDGFR Inhibitor Market grew from USD 3.43 billion in 2024 to USD 3.60 billion in 2025. It is expected to continue growing at a CAGR of 4.99%, reaching USD 4.59 billion by 2030.

This trajectory reflects expanded adoption of targeted therapies across major oncologic indications, as well as increased investment in next generation drug candidates. The primary keyword, PDGFR Inhibitor Market, is central to ongoing developments in chronic myeloid leukemia and gastrointestinal stromal tumor management, where advances in molecular profiling and tailored treatment are changing therapeutic approaches globally.

Scope & Segmentation

This report delivers in-depth analysis across the following dimensions, enabling leaders to pinpoint areas of opportunity and risk:

  • Indication: Chronic myeloid leukemia and gastrointestinal stromal tumors represent key focus areas, driven by evolving biomarker research and therapy refinement.
  • Drug Type: Monoclonal antibodies, including fully human and humanized formats, alongside first, second, and third generation small molecule inhibitors.
  • Delivery Route: Intravenous (via infusion and injection) and oral (capsule and tablet) modalities support tailored adherence programs and commercialization strategies.
  • End User: Ambulatory surgical centers, hospitals, and specialty clinics shape procurement and treatment access across different care settings.
  • Sales Channel: Hospital, online, and retail pharmacies create multiple distribution pathways addressing varying patient access needs.
  • Regional Coverage: Analysis spans the Americas (including the US, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notably the UK, Germany, France, and regional growth hubs), and Asia-Pacific (such as China, India, Japan, and emerging Southeast Asian markets).
  • Company Analysis: Novartis AG, Pfizer Inc., Bayer AG, Ipsen S.A., Exelixis, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., and Boehringer Ingelheim International GmbH.

Diverse delivery and drug innovations, along with focused regional and indication-based strategies, enable organizations to address evolving patient and regulatory requirements worldwide.

Key Takeaways for Senior Leaders

  • Strategic R&D investments in structure-guided molecule design and antibody development are redefining the pipeline’s competitive edge.
  • Market adoption is increasingly shaped by biomarker-driven patient segmentation and tailored drug regimens, necessitating adaptive trial designs and commercialization plans.
  • Collaboration across the pharmaceutical value chain, from contract development and manufacturing partnerships to academic alliances, is accelerating market access and innovation cycles.
  • The emergence of bispecific antibody constructs and allosteric inhibitors suggests a shifting landscape that prioritizes enhanced targeting and resistance mitigation.
  • Digital tools, artificial intelligence, and advanced analytics are streamlining lead identification and supply chain optimization, offering measurable process efficiencies.
  • Stakeholders should closely monitor regional reimbursement models and health technology assessment trends that directly influence therapy uptake and pricing structures.

Tariff Impact: U.S. Pharmaceutical Tariff Adjustments and Supply Chain Strategies

Forthcoming U.S. pharmaceutical tariff adjustments are anticipated to influence global supply chains by increasing landed costs for both active pharmaceutical ingredients and finished products. Organizational strategies are being transformed, with an emphasis on diversified supplier relationships, nearer-shore manufacturing, and digital inventory tracking to minimize disruption and maintain continuity of patient supply. Strategic engagement with trade authorities and the adoption of lean procurement models are essential for preserving margin and ensuring resilience in a shifting economic environment.

Methodology & Data Sources

This report synthesizes evidence from in-depth interviews with key opinion leaders and pharmaceutical executives. Supplementary secondary data from peer-reviewed journals, clinical registries, and market analytics systems provide comprehensive context and validation. Rigorous triangulation and peer-review protocols underpin all insights and conclusions.

PDGFR Inhibitor Market: Why This Report Matters

  • Delivers actionable guidance for portfolio optimization, strategic partnerships, and adaptive pricing in a rapidly advancing precision oncology landscape.
  • Empowers leadership by integrating robust data analysis with forward-looking assessments of regulatory, technological, and regional market dynamics.

Conclusion

The PDGFR Inhibitor Market is entering a period of dynamic evolution, underscored by scientific breakthroughs and intensifying global competition. Senior decision-makers can leverage these insights to inform strategy, manage risk, and seize new opportunities in targeted oncology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next-generation selective PDGFR inhibitors addressing resistance mutations and improving patient outcomes
5.2. Integration of PDGFR-targeted therapies with immuno-oncology regimens for enhanced antitumor efficacy in solid tumors
5.3. Advances in biomarker-driven patient selection for PDGFR inhibitor trials using liquid biopsy and genomic profiling
5.4. Expanding indications for PDGFR inhibitors beyond oncology into fibrotic diseases such as idiopathic pulmonary fibrosis
5.5. Development of oral PDGFR inhibitors with optimized pharmacokinetics to reduce dosing frequency and adverse effects
5.6. Strategic partnerships between biotech firms and big pharma to co-develop novel PDGFR inhibitor compounds
5.7. Utilization of real-world evidence to assess long-term safety and efficacy of PDGFR inhibitors across diverse patient populations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PDGFR Inhibitor Market, by Indication
8.1. Introduction
8.2. Chronic Myeloid Leukemia
8.3. Gastrointestinal Stromal Tumors
9. PDGFR Inhibitor Market, by Drug Type
9.1. Introduction
9.2. Monoclonal Antibody
9.2.1. Fully Human
9.2.2. Humanized
9.3. Small Molecule Inhibitor
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
10. PDGFR Inhibitor Market, by Delivery Route
10.1. Introduction
10.2. Intravenous
10.2.1. Infusion
10.2.2. Injection
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
11. PDGFR Inhibitor Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. PDGFR Inhibitor Market, by Sales Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas PDGFR Inhibitor Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa PDGFR Inhibitor Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific PDGFR Inhibitor Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Pfizer Inc.
16.3.3. Bayer AG
16.3.4. Ipsen S.A.
16.3.5. Exelixis, Inc.
16.3.6. Bristol-Myers Squibb Company
16.3.7. AstraZeneca PLC
16.3.8. Eli Lilly and Company
16.3.9. Merck & Co., Inc.
16.3.10. Boehringer Ingelheim International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PDGFR INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PDGFR INHIBITOR MARKET: RESEARCHAI
FIGURE 26. PDGFR INHIBITOR MARKET: RESEARCHSTATISTICS
FIGURE 27. PDGFR INHIBITOR MARKET: RESEARCHCONTACTS
FIGURE 28. PDGFR INHIBITOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PDGFR INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 114. CANADA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 115. CANADA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 116. CANADA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 117. CANADA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 118. CANADA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 119. CANADA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 120. CANADA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 121. CANADA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 122. CANADA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 123. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. CANADA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. CANADA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 134. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 135. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 222. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 223. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 224. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 225. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 226. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 227. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 240. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 241. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 242. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 243. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 244. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 245. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 250. FRANCE PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ITALY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 276. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 277. ITALY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 278. ITALY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 279. ITALY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 280. ITALY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 281. ITALY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 282. ITALY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 283. ITALY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 284. ITALY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 285. ITALY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 286. ITALY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 287. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. ITALY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. ITALY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 294. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 295. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 296. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 297. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 298. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 299. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 300. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 301. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 304. SPAIN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 328. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 346. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 348. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 350. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 352. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PDGFR Inhibitor market report include:
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Ipsen S.A.
  • Exelixis, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.59 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast 2025-2030 - Product Image

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Specialty Pharmaceuticals Market by Drug Type (Biologics, Biosimilars, Small Molecule Drugs), Product Type (Branded, Generics), Route Of Administration, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Specialty Pharmaceuticals Market by Drug Type (Biologics, Biosimilars, Small Molecule Drugs), Product Type (Branded, Generics), Route Of Administration, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
RAGE Inhibitor - Pipeline Insight, 2025 - Product Image

RAGE Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
HPK1 Inhibitors - Pipeline Insight, 2025 - Product Image

HPK1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Feiba VH Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Feiba VH Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.